Evidence map›Paper›PMID 25305755›Full record

ArticleNature genetics2014

Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.

Ming Zhang, Yuxuan Wang, Sian Jones, Mark Sausen, Kevin McMahon, Rajni Sharma, Qing Wang, Allan J Belzberg, Kaisorn Chaichana, Gary L Gallia and 10 more

Registry-linked trialAbstract read
In one paragraph

Article in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06114004 (Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcomas), which is not on this map. Cited by 174 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 4 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06114004 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Phase I/II Randomized Clinical Trial of Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcomas

TypeinterventionalSponsorAsociación Europea y Latinoamericana SELNET para la Investigación en SarcomasRan2023 to 2026Enrolled88ConditionsSarcoma,Soft TissueArmsSelinexor 20 MG, Gemcitabine
3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 4 syntheses or guidelines pooled it, 312 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Ming Zhang1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Yuxuan Wang1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sian JonesPersonalized Genome Diagnostics, Baltimore, Maryland, USA.
Mark SausenPersonalized Genome Diagnostics, Baltimore, Maryland, USA.
Kevin McMahon1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rajni SharmaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Qing Wang1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Allan J BelzbergDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kaisorn ChaichanaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gary L GalliaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ziya L GokaslanDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Greg J RigginsDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jean-Paul WolinksyDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Laura D WoodDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Elizabeth A MontgomeryDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Ralph H HrubanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Kenneth W Kinzler1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nickolas Papadopoulos1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Bert Vogelstein1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Chetan Bettegowda1] Ludwig Center for Cancer Genetics, Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA. [2] Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. [3] Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins Medicine · USJohns Hopkins University · USHoward Hughes Medical Institute · USCancer Genetics (United States) · USHuman Genome Sciences (United States) · USSidney Kimmel Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Genes from the FAP LocusR37CA057345 · NCI · JOHNS HOPKINS UNIVERSITY · PI KINZLER, KENNETH W. · 2002 to 2016
$7.4M
NCI NIH HHS P30 CA006973NCI NIH HHS R37 CA057345NIGMS NIH HHS T32 GM007309
6 · The paper itself

Abstract

Neurofibromatosis 1 is a hereditary syndrome characterized by the development of numerous benign neurofibromas, a small subset of which progress to malignant peripheral nerve sheath tumors (MPNSTs). To better understand the genetic basis for MPNSTs, we performed genome-wide or targeted sequencing on 50 cases. Sixteen MPNSTs but none of the neurofibromas tested were found to have somatic mutations in SUZ12, implicating it as having a central role in malignant transformation.

Indexed as

Base SequenceComputational BiologyHumansImmunohistochemistryMolecular Sequence DataMutationNeoplasm ProteinsNeurilemmomaOligonucleotide Array Sequence AnalysisPolycomb Repressive Complex 2Sequence Analysis, DNATranscription FactorsNeoplasm ProteinsPolycomb Repressive Complex 2SUZ12 protein, humanTranscription Factors

Identifiers

PMID25305755
PMCPMC4383254
OpenAlexW1987937498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.